← Eichor
Study identifier: NCT06962371 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

Condition: Transcatheter Aortic Valve Implantation (TAVI) · Aortic Valve Stenosis · Transcatheter Aortic Valve Replacement  ·  Sponsor: Transverse Medical, Inc.

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.

This description comes directly from the study's public registry record.

Talk to the study team

Erin Spiegel, PhD  ·  +13033252945  ·  erin.spiegel@transversemedical.com

Blair Holman  ·  +13033252945  ·  blair.holman@transversemedical.com

Always discuss trial participation with your own doctor first.

Locations (1)

Victorian Heart HospitalClayton, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06962371